Moldóva - rúmenska - AMDM (Agenţia Medicamentului şi Dispozitivelor Medicale)

kusum healthcare pvt.ltd - metronidazolum - ovule - 500 mg

Evrópusambandið - rúmenska - EMA (European Medicines Agency)

bayer ag - riociguat - hipertensiune arterială, pulmonară - antihipertensive pentru hipertensiunea arterială pulmonară - chronic thromboembolic pulmonary hypertension (cteph)adempas is indicated for the treatment of adult patients with who functional class (fc) ii to iii withinoperable cteph,persistent or recurrent cteph after surgical treatment,to improve exercise capacity. pulmonary arterial hypertension (pah)adultsadempas, as monotherapy or in combination with endothelin receptor antagonists, is indicated for the treatment of adult patients with pulmonary arterial hypertension (pah) with who functional class (fc) ii to iii to improve exercise capacity. eficacitatea a fost demonstrată într-un hap populației, inclusiv etiologii ale idiopatică sau ereditară pah sau htap asociată bolilor de țesut conjunctiv. paediatricsadempas is indicated for the treatment of pah in paediatric patients aged less than 18 years of age and body weight ≥ 50 kg with who functional class (fc) ii to iii in combination with endothelin receptor antagonists.

Evrópusambandið - rúmenska - EMA (European Medicines Agency)

sanofi winthrop industrie - dronedaronă - fibrilatie atriala - terapia cardiacă - multaq este indicat pentru mentinerea ritmului sinusal dupa cardioversie de succes la pacienţii adulţi clinic stabil cu fibrilatie atriala paroxistica sau persistente (af). datorită profilului său de siguranță, multaq trebuie prescris numai după luarea în considerare a opțiunilor de tratament alternative. multaq nu trebuie administrat la pacienții cu disfuncție sistolică de ventricul stâng sau la pacienții cu curent sau anterior episoade de insuficiență cardiacă.

Rúmenía - rúmenska - ANMDM (Agentia Nationala a Medicamentului si a Dispozitivelor Medicale)

orion corporation - finlanda - levosimendanum - conc. pt. sol. perf. - 2,5mg/ml - stimulante cardiace excl. glicozizi cardiotonici alte stimulante cardiace

Moldóva - rúmenska - AMDM (Agenţia Medicamentului şi Dispozitivelor Medicale)

zdorovie srl, companie farmaceutica - propranololum - comprimate - 10 mg

Moldóva - rúmenska - AMDM (Agenţia Medicamentului şi Dispozitivelor Medicale)

gntls srl, uzina experimentala - strophanthinum - solutie injectabila - 0,25 mg/ml

Evrópusambandið - rúmenska - EMA (European Medicines Agency)

novartis europharm ltd. - aliskiren - hipertensiune - agenți care acționează asupra sistemului renină-angiotensină - tratamentul hipertensiunii esențiale.

Evrópusambandið - rúmenska - EMA (European Medicines Agency)

biontech manufacturing gmbh - single-stranded, 5’-capped messenger rna produced using a cell-free in vitro transcription from the corresponding dna templates, encoding the viral spike (s) protein of sars-cov-2 - covid-19 virus infection - vaccinuri - comirnaty 30 micrograms/dose concentrate for dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in individuals 12 years of age and older.  comirnaty 30 micrograms/dose dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in individuals 12 years of age and older.  comirnaty 10 micrograms/dose concentrate for dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in children aged 5 to 11 years.  comirnaty 3 micrograms/dose concentrate for dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in infants and children aged 6 months to 4 years.  comirnaty original/omicron ba. 1 (15/15 micrograms)/dose dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in individuals 12 years of age and older who have previously received at least a primary vaccination course against covid-19. comirnaty original/omicron ba. 4-5 (15/15 micrograms)/dose dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in individuals 12 years of age and older. comirnaty original/omicron ba. 4-5 (5/5 micrograms)/dose concentrate for dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in children aged 5 to 11 years. comirnaty original/omicron ba. 4-5 (5/5 micrograms)/dose dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in children aged 5 to 11 years.  comirnaty original/omicron ba. 4-5 (1. 5/1. 5 micrograms)/dose concentrate for dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in infants and children aged 6 months to 4 years.  comirnaty omicron xbb. 5 30 micrograms/dose dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in individuals 12 years of age and older. comirnaty omicron xbb. 5 10 micrograms/dose concentrate for dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in children aged 5 to 11 years. comirnaty omicron xbb. 5 10 micrograms/dose dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in children aged 5 to 11 years. comirnaty omicron xbb. 5 3 micrograms/dose concentrate for dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in infants and children aged 6 months to 4 years. utilizarea acestui vaccin ar trebui să fie în conformitate cu recomandările oficiale.

Moldóva - rúmenska - AMDM (Agenţia Medicamentului şi Dispozitivelor Medicale)

farmaco sa, im - sildenafilum - comprimate - 35 mg

Moldóva - rúmenska - AMDM (Agenţia Medicamentului şi Dispozitivelor Medicale)

farmaco sa, im - sildenafilum - comprimate - 70 mg